The Potential Impact of Pre-Exposure Prophylaxis for HIV Prevention among Men Who Have Sex with Men and Transwomen in Lima, Peru: A Mathematical Modelling Study

English version České info

Background:
HIV pre-exposure prophylaxis (PrEP), the use of antiretroviral drugs by uninfected individuals to prevent HIV infection, has demonstrated effectiveness in preventing acquisition in a high-risk population of men who have sex with men (MSM). Consequently, there is a need to understand if and how PrEP can be used cost-effectively to prevent HIV infection in such populations.

Methods and Findings:
We developed a mathematical model representing the HIV epidemic among MSM and transwomen (male-to-female transgender individuals) in Lima, Peru, as a test case. PrEP effectiveness in the model is assumed to result from the combination of a “conditional efficacy” parameter and an adherence parameter. Annual operating costs from a health provider perspective were based on the US Centers for Disease Control and Prevention interim guidelines for PrEP use. The model was used to investigate the population-level impact, cost, and cost-effectiveness of PrEP under a range of implementation scenarios. The epidemiological impact of PrEP is largely driven by programme characteristics. For a modest PrEP coverage of 5%, over 8% of infections could be averted in a programme prioritising those at higher risk and attaining the adherence levels of the Pre-Exposure Prophylaxis Initiative study. Across all scenarios, the highest estimated cost per disability-adjusted life year averted (uniform strategy for a coverage level of 20%, US$1,036–US$4,254) is below the World Health Organization recommended threshold for cost-effective interventions, while only certain optimistic scenarios (low coverage of 5% and some or high prioritisation) are likely to be cost-effective using the World Bank threshold. The impact of PrEP is reduced if those on PrEP decrease condom use, but only extreme behaviour changes among non-adherers (over 80% reduction in condom use) and a low PrEP conditional efficacy (40%) would adversely impact the epidemic. However, PrEP will not arrest HIV transmission in isolation because of its incomplete effectiveness and dependence on adherence, and because the high cost of programmes limits the coverage levels that could potentially be attained.

Conclusions:
A strategic PrEP intervention could be a cost-effective addition to existing HIV prevention strategies for MSM populations. However, despite being cost-effective, a substantial expenditure would be required to generate significant reductions in incidence.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: The Potential Impact of Pre-Exposure Prophylaxis for HIV Prevention among Men Who Have Sex with Men and Transwomen in Lima, Peru: A Mathematical Modelling Study. PLoS Med 9(10): e32767. doi:10.1371/journal.pmed.1001323
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001323

Souhrn

Zdroje

1. AVAC Global Advocacy for HIV Prevention (20120 Pre-exposure prophylaxis (PrEP). Available: http://www.avac.org/ht/d/sp/i/262/pid/262. Accessed 5 September 2012.

2. GrantRM, LamaJR, AndersonPL, McMahanV, LiuAY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587–2599.

3. Centers for Disease Control and Prevention (2011) Interim guidance: preexposure prophylaxis for the prevention of HIV Infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 60: 65–68.

4. Southern African HIV Clinicians Society Consensus Committee (2012) Guidelines for the safe use of pre-exposure prophylaxis in men who have sex with men who are at risk for HIV infection. S Afr J HIV Med 13: 40–55.

5. McCormackS, FidlerS, FisherM (2012) The British HIV Association/British Association for Sexual Health and HIV position statement on pre-exposure prophylaxis in the UK. Int J STD AIDS 23: 1–4.

6. World Health Organization (2012) Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects. Available: http://apps.who.int/iris/bitstream/10665/75188/1/9789241503884_eng.pdf. Accessed 29 August 2012.

7. US Food and Drug Administration (2012 July 16) FDA approves first drug for reducing the risk of sexually acquired HIV infection. Available: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm. Accessed 29 August 2012.

8. BaetenJM, DonnellD, NdaseP, MugoNR, CampbellJD, et al. (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 367: 399–410.

9. ThigpenMC, KebaabetswePM, PaxtonLA, SmithDK, RoseCE, et al. (2012) Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 367: 423–434.

10. Van DammeL, CorneliA, AhmedK, AgotK, LombaardJ, et al. (2012) Preexposure prophylaxis for HIV infection among African women. N Engl J Med 367: 411–422.

11. Abdool KarimQ, Abdool KarimSS, FrohlichJA, GroblerAC, BaxterC, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168–1174.

12. Microbicide Trials Network (2011 September 28) Microbicide Trials Network statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in Women. Available: http://www.mtnstopshiv.org/node/3619. Accessed 29 August 2012.

13. StoverJ (2011) HIV models to inform health policy. Curr Opin HIV AIDS 6: 108–113.

14. BeyrerC, BaralSD, WalkerD, WirtzAL, JohnsB, et al. (2010) The expanding epidemics of HIV type 1 among men who have sex with men in low- and middle-income countries: diversity and consistency. Epidemiol Rev 32: 137–151.

15. CaceresCF, KondaK, SeguraER, LyerlaR (2008) Epidemiology of male same-sex behaviour and associated sexual health indicators in low- and middle-income countries: 2003–2007 estimates. Sex Transm Infect 84 (Suppl 1) i49–i56.

16. CaceresCF, KondaKA, SalazarX, LeonSR, KlausnerJD, et al. (2008) New populations at high risk of HIV/STIs in low-income, urban coastal Peru. AIDS Behav 12: 544–551.

17. ClarkJL, KondaKA, SeguraER, SalvatierraHJ, LeonSR, et al. (2008) Risk factors for the spread of HIV and other sexually transmitted infections among men who have sex with men infected with HIV in Lima, Peru. Sex Transm Infect 84: 449–454.

18. ClarkJL, CaceresCF, LescanoAG, KondaKA, LeonSR, et al. (2007) Prevalence of same-sex sexual behavior and associated characteristics among low-income urban males in Peru. PLoS ONE 2: e778 doi:10.1371/journal.pone.0000778.

19. SanchezJ, LamaJR, KusunokiL, ManriqueH, GoicocheaP, et al. (2007) HIV-1, sexually transmitted infections, and sexual behavior trends among men who have sex with men in Lima, Peru. J Acquir Immune Defic Syndr 44: 578–585.

20. SanchezJ, LamaJR, PeinadoJ, ParedesA, LucchettiA, et al. (2009) High HIV and ulcerative sexually transmitted infection incidence estimates among men who have sex with men in Peru: awaiting for an effective preventive intervention. J Acquir Immune Defic Syndr 51 (Suppl 1) S47–S51.

21. Silva-SantistebanA, RaymondHF, SalazarX, VillayzanJ, LeonS, et al. (2011) Understanding the HIV/AIDS epidemic in transgender women of Lima, Peru: results from a sero-epidemiologic study using respondent driven sampling. AIDS Behav 16: 872–881.

22. Abu-RaddadLJ, PatnaikP, KublinJG (2006) Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science 314: 1603–1606.

23. HallettTB, SinghK, SmithJA, WhiteRG, Abu-RaddadLJ, et al. (2008) Understanding the impact of male circumcision interventions on the spread of HIV in southern Africa. PLoS ONE 3: e2212 doi:10.1371/journal.pone.0002212.

24. StrathdeeSA, HallettTB, BobrovaN, RhodesT, BoothR, et al. (2010) HIV and risk environment for injecting drug users: the past, present, and future. Lancet 376: 268–284.

25. HollingsworthTD, AndersonRM, FraserC (2008) HIV-1 transmission, by stage of infection. J Infect Dis 198: 687–693.

26. EggerM, MayM, CheneG, PhillipsAN, LedergerberB, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360: 119–129.

27. AlkemaL, RafteryAE, ClarkSJ (2007) Probabilistic projections of HIV prevalence using Bayesian melding. Ann Appl Stat 229–248.

28. PooleD, RafteryAE (2000) Inference for deterministic simulation models: the Bayesian melding approach. J Am Stat Assoc 95: 1244–1255.

29. BlowerS, DowlatabadiH (1994) Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int Stat Rev 62: 229–243.

30. Anderson PL, Liu A, Buchbinder S, Lama JR, Guanira J, et al.. (2012) Intracellular tenofovir-diphosphate (TFV-DP) concentrations associated with PrEP efficacy in men who have sex with men (MSM) from iPrEx [abstract]. 19th Conference on Retroviruses and Opportunistics Infections; 5–8 Mar 2012; Seattle, Washington, US.

31. Joint United Nations Programme on HIV/AIDS (2009) Informe nacional sobre los progresos realizados en el país: Peru—periodo enero 2010–diciembre 2011. Available: http://www.unaids.org/es/dataanalysis/knowyourresponse/countryprogressreports/2012countries/file,68900,es..pdf. Accessed 5 September 2012.

32. Joint United Nations Programme on HIV/AIDS (2004 February) Costing guidelines for HIV/AIDS intervention strategies for use in estimating resource needs, scaling-up and strategic planning in the Asia/Pacific region. Geneva: Joint United Nations Programme on HIV/AIDS.

33. Gilead (2012) Tiered pricing. Available: http://www.gilead.com/enabling_access. Accessed 29 August 2012.

34. World Health Organization (2003) Making choices in health: WHO guide to cost-effectiveness analysis Geneva: World Health Organization.

35. Fox-RushbyJA, HansonK (2001) Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan 16: 326–331.

36. Lopez de CastillaD, VerdonckK, OteroL, IglesiasD, EchevarriaJ, et al. (2008) Predictors of CD4+ cell count response and of adverse outcome among HIV-infected patients receiving highly active antiretroviral therapy in a public hospital in Peru. Int J Infect Dis 12: 325–331.

37. World Health Organization (2004) Global burden of disease 2004 update: disability weights for diseases and conditions. Available: http://www.who.int/healthinfo/global_burden_disease/GBD2004_DisabilityWeights.pdf. Accessed 29 August 2012.

38. AldridgeRW, IglesiasD, CaceresCF, MirandaJJ (2009) Determining a cost effective intervention response to HIV/AIDS in Peru. BMC Public Health 9: 352.

39. PretoriusC, StoverJ, BollingerL, BacaerN, WilliamsB (2010) Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS ONE 5: e13646 doi:10.1371/journal.pone.0013646.

40. Ministerio de Salud del Perú (2004) Plan de la estrategia sanitaria nacional de prevención y control de las ITS-VIH/SIDA 2005–2009. Lima: Ministerio de Salud del Perú.

41. ShillcuttSD, WalkerDG, GoodmanCA, MillsAJ (2009) Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 27: 903–917.

42. World Bank (2012) GDP per capita (current US$) [database]. Available: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed 29 August 2012.

43. World Bank (1993) World development report. Washington (District of Columbia): World Bank.

44. Aran-MateroD, AmicoP, Aran-FernandezC, GobetB, Izazola-LiceaJA, et al. (2011) Levels of spending and resource allocation to HIV programs and services in Latin America and the Caribbean. PLoS ONE 6: e22373 doi:10.1371/journal.pone.0022373.

45. Global Fund to Fight AIDS, Tuberculosis and Malaria (2012) Peru: regional grant portfolio. Available: http://portfolio.theglobalfund.org/en/Country/Index/PER. Accessed 5 September 2012.

46. DesaiK, SansomSL, AckersML, StewartSR, HallHI, et al. (2008) Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 22: 1829–1839.

47. PaltielAD, FreedbergKA, ScottCA, SchackmanBR, LosinaE, et al. (2009) HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 48: 806–815.

48. KoppenhaverRT, SorensenSW, FarnhamPG, SansomSL (2011) The cost-effectiveness of pre-exposure prophylaxis in men who have sex with men in the United States: an epidemic model. J Acquir Immune Defic Syndr 58: e51–e52.

49. JuusolaJL, BrandeauML, OwensDK, BendavidE (2012) The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med 156: 541–550.

50. AbbasUL, AndersonRM, MellorsJW (2007) Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS ONE 2: e875 doi:10.1371/journal.pone.0000875.

51. HallettTB, BaetenJM, HeffronR, BarnabasR, de BruynG, et al. (2011) Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 8: e1001123 doi:10.1371/journal.pmed.1001123.

52. Abbas UL, Glaubius R, Mubayi A, Hood G, Mellors JW (2011) Predicting the impact of ART and PrEP with overlapping regimens on HIV transmission and drug resistance in South Africa [abstract]. 18th Conference on Retroviruses and Opportunistic Infections; 27 Feb–2 Mar 2011; Boston, Massachusetts, US.

53. SupervieV, Garcia-LermaJG, HeneineW, BlowerS (2010) HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci U S A 107: 12381–12386.

54. StoverJ, BertozziS, GutierrezJP, WalkerN, StaneckiKA, et al. (2006) The global impact of scaling up HIV/AIDS prevention programs in low- and middle-income countries. Science 311: 1474–1476.